Search Page

1

Cite

Share

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.

Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN. Jones WD, et al. Among authors: braicu i. Cancers (Basel). 2020 Mar 7;12(3):620. doi: 10.3390/cancers12030620. Cancers (Basel). 2020. PMID: 32156016 Free PMC article.

Cite

Share

2

Cite

Share

GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis.

Cabral-Marques O, Marques A, Giil LM, De Vito R, Rademacher J, Günther J, Lange T, Humrich JY, Klapa S, Schinke S, Schimke LF, Marschner G, Pitann S, Adler S, Dechend R, Müller DN, Braicu I, Sehouli J, Schulze-Forster K, Trippel T, Scheibenbogen C, Staff A, Mertens PR, Löbel M, Mastroianni J, Plattfaut C, Gieseler F, Dragun D, Engelhardt BE, Fernandez-Cabezudo MJ, Ochs HD, Al-Ramadi BK, Lamprecht P, Mueller A, Heidecke H, Riemekasten G. Cabral-Marques O, et al. Among authors: braicu i. Nat Commun. 2018 Dec 6;9(1):5224. doi: 10.1038/s41467-018-07598-9. Nat Commun. 2018. PMID: 30523250 Free PMC article.

Cite

Share

3

Cite

Share

miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.

Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: braicu i. Int J Cancer. 2020 Dec 15;147(12):3560-3573. doi: 10.1002/ijc.33182. Epub 2020 Aug 1. Int J Cancer. 2020. PMID: 32621752 Review.

Cite

Share

4

Cite

Share

Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer.

Könsgen D, Klinkmann G, Kaul A, Diesing K, Sehouli J, Braicu I, Sümnig A, Erb HHH, Stope MB, Mustea A. Könsgen D, et al. Among authors: braicu i. Eur J Obstet Gynecol Reprod Biol. 2020 Dec;255:154-159. doi: 10.1016/j.ejogrb.2020.10.044. Epub 2020 Oct 21. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 33130378

Cite

Share

5

Cite

Share

Transfusion of red blood cells does not impact progression-free and overall survival after surgery for ovarian cancer.

Hunsicker O, Gericke S, Graw JA, Krannich A, Boemke W, Meyer O, Braicu I, Spies C, Sehouli J, Pruß A, Feldheiser A. Hunsicker O, et al. Among authors: braicu i. Transfusion. 2019 Dec;59(12):3589-3600. doi: 10.1111/trf.15552. Epub 2019 Oct 21. Transfusion. 2019. PMID: 31633819

Cite

Share

6

Cite

Share

miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.

Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: braicu i. Carcinogenesis. 2020 Jun 17;41(4):442-451. doi: 10.1093/carcin/bgz163. Carcinogenesis. 2020. PMID: 31586203

Cite

Share

7

Cite

Share

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N. Ray-Coquard I, et al. Among authors: braicu i. Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019. Front Oncol. 2019. PMID: 31552170 Free PMC article.

Cite

Share

8

Cite

Share

Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors.

Vasconcelos I, Olschewski J, Braicu I, Sehouli J. Vasconcelos I, et al. Among authors: braicu i. Eur J Obstet Gynecol Reprod Biol. 2015 Mar;186:26-33. doi: 10.1016/j.ejogrb.2014.12.022. Epub 2015 Jan 10. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 25602531 Review.

Cite

Share

9

Cite

Share

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S. Stanske M, et al. Among authors: braicu i. Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22. Neoplasia. 2018. PMID: 29466768 Free PMC article.

Cite

Share

10

Cite

Share

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.

Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN. Patel JN, et al. Among authors: braicu i. Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318511 Free PMC article.

Cite

Share